TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The CDC’s updated 2026 Antimicrobial Resistance Threats Report lists 19 pathogens at urgent, serious or concerning levels and six additional organisms on a watch list. Together, the pathogens are estimated to cause 9.7 million infections and 50,800 deaths annually in the United States; the report also records a drop in C. difficile’s threat category.
The CDC’s updated 2026 antimicrobial resistance report identifies 19 pathogens as urgent, serious or concerning threats and places six others on a watch list, estimating that the organisms together cause 9.7 million infections and 50,800 deaths annually in the United States. Four drug-resistant pathogens are in the agency’s top-tier urgent category, while Clostridioides difficile moved down from that category to serious.
The four urgent threats are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae. The CDC identifies these organisms as requiring aggressive action. The report also assigns drug-resistant N. meningitidis to the serious category, which calls for prompt, sustained action.
The report gives examples of the burden from individual pathogens. Carbapenem-resistant Acinetobacter was associated with 9,497 U.S. hospitalizations in 2023 and an estimated 817 deaths that year. Carbapenem-resistant Enterobacterales were associated with 14,878 hospitalizations and an estimated 1,252 deaths in 2023. Those figures are specific to each pathogen and year; they are not the same as the report’s combined annual estimate for all listed threats.
Drug-resistant gonorrhea caused an estimated 787,000 U.S. infections in 2023, according to the source report. It says 55.4% of gonorrhea cases that year were resistant to at least one of six antibiotics or had elevated minimum inhibitory concentrations. The FDA approved gepotidacin and zoliflodacin for gonorrhea in 2025, described in the source as the first new antibiotics for the infection in decades.
Threat Rankings and Patient Care
Antimicrobial resistance can make infections harder to treat when medicines that once worked become less effective. The report’s findings matter beyond the infections themselves: resistant pathogens can complicate care for people who need surgery, cancer treatment or other procedures where preventing and treating infection is important.
Wendy Armstrong, president of the Infectious Diseases Society of America, said in a statement that resistant infections can prolong hospital stays and increase health-care costs. She also warned that they can make it harder for clinicians to safely provide care such as chemotherapy, transplants and joint replacements. Those are her stated concerns about the consequences of resistance, not individual outcomes quantified by the report.
The report also points to changes in the threat picture, rather than a simple rise across every pathogen. The CDC lowered C. difficile’s ranking, while adding emerging organisms to its watch list. These classifications help direct attention, but the source material does not say that a category change alone predicts a patient’s personal risk.
Products Worth Considering
Levoit Eleva 300X HEPA Air Purifier for Home and Bedroom
Hyperice Normatec Elite Wireless Compression Boots
Fitbit Versa Smart Watch – Black Aluminum, One Size (S & L Bands Included)
As an affiliate, we earn on qualifying purchases.
New Additions and Category Changes
The updated report includes six organisms on a watch list of potential threats whose disease burden is uncertain. The additions named in the source are drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria. The source does not identify all six watch-list organisms, so the list should not be treated as complete here.
C. difficile shifted from urgent to serious. The source report attributes the change in part to successful infection-prevention measures and a decline in cases since 2011. That category change does not mean the infection is no longer a public-health concern; the CDC still places it among serious threats.
The source also reports a marked rise in U.S. C. auris cases: from 48 reported cases in 2016, when it was first reported in the country, to 4,523 in 2023. C. auris is a multidrug-resistant yeast that can cause severe infections, especially in people who are already seriously ill. These figures describe reported cases in those years, not an annual rate of increase.
“These numbers are alarming by any measure, but they are particularly sobering when infectious diseases physicians connect real patients with these statistics in their everyday experience.”
— Wendy Armstrong, president of the Infectious Diseases Society of America
Limits of the Current Estimates
The combined figures of 9.7 million infections and 50,800 deaths per year are CDC estimates for the pathogens covered by the report. The source material does not provide the estimate’s methodology, uncertainty range or a year-by-year breakdown, so those details cannot be assessed here. The individual hospitalization and death figures cited above refer specifically to 2023.
The watch-list organisms are described as potential threats with uncertain disease burdens. The supplied report summary also does not provide details on how the agency will measure changes in those organisms, or the full set of pathogens in each category. It is not clear from the source whether the overall annual estimate represents a change from the previous report or how much of any change reflects surveillance or classification updates.
Policy and Surveillance Ahead
The CDC’s revised rankings put attention on pathogens it considers the most pressing and on emerging organisms whose impact remains uncertain. Continued tracking will be needed to clarify how case burdens and resistance patterns change, particularly for watch-list pathogens and drug-resistant infections with limited treatment options.
Armstrong called for passage of the PASTEUR Act, which would create a federal program to support development of antimicrobial drugs targeting threatening pathogens and infections. According to the source report, versions of the bill remain stalled in congressional committees. No legislative timetable or next committee action is specified in the material available.
Key Questions
How many infections and deaths does the CDC estimate these pathogens cause?
The CDC estimates that the pathogens covered by its 2026 report cause 9.7 million infections and 50,800 deaths annually in the United States. The source summary does not give a methodology or uncertainty range for those combined estimates.
Which pathogens are in the CDC’s urgent category?
The four urgent threats named in the report are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.
Why did C. difficile move to a lower threat category?
The source says C. difficile moved from urgent to serious, in part because infection-prevention measures have been successful and case numbers have fallen since 2011. It remains classified as a serious threat.
What is the CDC watch list?
It is a list of potential threats for which the disease burden is uncertain. The source names drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria among the additions, but does not provide the full six-organism list.
What does the PASTEUR Act propose?
According to the source report, the proposed federal program would support development of antimicrobial drugs for the most threatening pathogens and infections. The bill’s versions remain stalled in congressional committees, and the source does not give a timeline for further action.
Source: medpagetoday.com
